| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, NB Dahir, PZ Proszek, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 616 | 2015 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 341 | 2014 |
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma MF Kaiser, DC Johnson, P Wu, BA Walker, A Brioli, F Mirabella, ... Blood, The Journal of the American Society of Hematology 122 (2), 219-226, 2013 | 193 | 2013 |
| Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns AS Moore, A Faisal, DG De Castro, V Bavetsias, C Sun, B Atrash, ... Leukemia 26 (7), 1462-1470, 2012 | 140 | 2012 |
| Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control C Pawlyn, MD Bright, AF Buros, CK Stein, Z Walters, LI Aronson, ... Blood cancer journal 7 (3), e549-e549, 2017 | 112 | 2017 |
| Improved risk stratification in myeloma using a micro RNA‐based classifier P Wu, L Agnelli, BA Walker, K Todoerti, M Lionetti, DC Johnson, M Kaiser, ... British journal of haematology 162 (3), 348-359, 2013 | 63 | 2013 |
| MMSET is the key molecular target in t (4; 14) myeloma F Mirabella, P Wu, CP Wardell, MF Kaiser, BA Walker, DC Johnson, ... Blood cancer journal 3 (5), e114-e114, 2013 | 63 | 2013 |
| HSF1 is essential for myeloma cell survival and a promising therapeutic target JHL Fok, S Hedayat, L Zhang, LI Aronson, F Mirabella, C Pawlyn, ... Clinical Cancer Research 24 (10), 2395-2407, 2018 | 58 | 2018 |
| A conserved insulator that recruits CTCF and cohesin exists between the closely related but divergently regulated interleukin-3 and granulocyte-macrophage colony-stimulating … SR Bowers, F Mirabella, FJ Calero-Nieto, S Valeaux, S Hadjur, EW Baxter, ... Molecular and cellular biology 29 (7), 1682-1693, 2009 | 43 | 2009 |
| Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression N Li, DC Johnson, N Weinhold, JB Studd, G Orlando, F Mirabella, ... Nature communications 7 (1), 13656, 2016 | 42 | 2016 |
| Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress L Zhang, JJL Fok, F Mirabella, LI Aronson, RA Fryer, P Workman, ... Cancer letters 339 (1), 49-59, 2013 | 42 | 2013 |
| The human IL-3/granulocyte-macrophage colony-stimulating factor locus is epigenetically silent in immature thymocytes and is progressively activated during T cell development F Mirabella, EW Baxter, M Boissinot, SR James, PN Cockerill The Journal of Immunology 184 (6), 3043-3054, 2010 | 31 | 2010 |
| Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical … LI Aronson, EL Davenport, F Mirabella, GJ Morgan, FE Davies Leukemia 27 (12), 2397-2403, 2013 | 30 | 2013 |
| Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology M Went, A Sud, H Speedy, NJ Sunter, A Försti, PJ Law, DC Johnson, ... Blood cancer journal 9 (1), 1, 2018 | 18 | 2018 |
| The inducible tissue-specific expression of the human IL-3/GM-CSF locus is controlled by a complex array of developmentally regulated enhancers EW Baxter, F Mirabella, SR Bowers, SR James, AM Bonavita, E Bertrand, ... The Journal of Immunology 189 (9), 4459-4469, 2012 | 11 | 2012 |
| A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex F Mirabella, A Murison, LI Aronson, CP Wardell, AJ Thompson, ... PloS one 9 (6), e99493, 2014 | 9 | 2014 |
| The novel protein HSF1 stress pathway inhibitor bisamide CCT361814 demonstrates pre-clinical anti-tumor activity in myeloma K Menezes, G Aram, F Mirabella, DC Johnson, AL Sherborne, ... Blood 130, 3072, 2017 | 5 | 2017 |
| Identifying ultra-high risk myeloma by integrated molecular genetic and gene expression profiling AL Sherborne, A Price, DC Johnson, S Ellis, C Smith, F Mirabella, ... Blood 128 (22), 4407, 2016 | 4 | 2016 |
| Inhibition of the epigenetic modifier EZH2 upregulates cell cycle control genes to inhibit myeloma cell growth and overcome high-risk disease features C Pawlyn, M Bright, A Buros, CK Stein, Z Walters, L Aronson, F Mirabella, ... Blood 128 (22), 3289, 2016 | 3 | 2016 |
| EZH2 overexpression in myeloma patients shortens survival and in-vitro data supports a potential new targeted treatment strategy C Pawlyn, M Kaiser, A Buros, C Stein, V Macleod, F Mirabella, J Fok, ... Clinical Lymphoma, Myeloma and Leukemia 15, e213, 2015 | 2 | 2015 |
Brian A WalkerIndiana UniversityVerified email at iu.edu
